Equities

Assembly Biosciences Inc

Assembly Biosciences Inc

Actions
  • Price (EUR)15.40
  • Today's Change-0.45 / -2.84%
  • Shares traded310.00
  • 1 Year change+89.28%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 20:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments13092147
Total Receivables, Net0.040.940.34
Total Inventory------
Prepaid expenses3.504.417.24
Other current assets, total------
Total current assets13497154
Property, plant & equipment, net2.723.947.18
Goodwill, net----0
Intangibles, net----0
Long term investments--028
Note receivable - long term------
Other long term assets0.310.891.70
Total assets137102191
LIABILITIES
Accounts payable0.462.492.66
Accrued expenses7.851413
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total31----
Total current liabilities391616
Total long term debt000
Total debt000
Deferred income tax----0
Minority interest------
Other liabilities, total572.836.06
Total liabilities961922
SHAREHOLDERS EQUITY
Common stock0.010.050.05
Additional paid-in capital827808801
Retained earnings (accumulated deficit)(786)(725)(631)
Treasury stock - common------
Unrealized gain (loss)(0.08)(0.8)(0.42)
Other equity, total------
Total equity4183169
Total liabilities & shareholders' equity137102191
Total common shares outstanding5.484.074.01
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.